Articles
Questions / Evidence / Ideas
A place for closer reading. Articles on the questions, methods and documents behind peptide research.
Our editorial approachRead peptide HPLC results through separation behavior, analytical purpose and validation evidence, with clear limits on purity claims.
Compare FDA statements on sterility-test limits and endotoxin assay suitability, with a focus on the separate claims each record supports.
Use SELECT to read a peptide-medicine trial’s population, comparator, endpoints, follow-up and subgroup analysis without overstating the evidence.
More to explore.
Continue through the collectionA review-based guide to detemir and degludec, separating structural modifications, release mechanisms and gaps in safety and clinical evidence.
How FDA and ICH documents distinguish identity, strength, purity, endotoxin and sterility claims in peptide laboratory reports.
Examine oxytocin receptor signaling through computational models, cell calcium assays and rat tracer data, with clear boundaries for each finding.
Learn to identify a peptide review, trace claims to original experiments and keep study models separate from conclusions about peptide performance.
Compare an oxytocin trial in children with a mouse experiment, keeping study models, administration routes and measured outcomes in context.
A source-led look at insulin receptor activation, designed binding proteins and the evidence needed to assess insulin analogue claims.
Separate sterility, endotoxin and purity claims using FDA and EMA records, with attention to method purpose and material-specific suitability.
How peptide reference materials support calibration and comparison, with NIST definitions and an OSPP study showing the scope of analytical claims.
Learn to read peptide structure records through sequence links, experimental validation, resolution and computed-model confidence.
Read peptide LC-MS identity findings in context, with original evidence separating identity confirmation from purity, sequence and quantity claims.
An in vitro bivalirudin NMR study illustrates why peptide characterization claims should stay tied to the methods and variants actually examined.
A focused look at GLP-1R experiments linking receptor location, local signaling and cellular responses, with each finding kept within its study model.
Use ICH and FDA guidance to separate peptide identity, purity and strength claims, assess validation evidence, and read certificates within their scope.
Review peptide COAs by connecting sample identifiers, methods, results and laboratory roles while separating document completeness from analytical support.
FDA guidance on recombinant endotoxin methods and sterility testing shows why peptide quality claims must stay tied to specific records.
Connect peptide names with sequences, modifications, salt definitions and analytical records while keeping each source's evidence scope clear.
A source-led framework for reading peptide purity reports, distinguishing analytical purposes and assessing the evidence behind validation claims.
Read peptide analytical results by purpose, using ICH Q2(R2) to distinguish identity, purity, impurities and assay/potency claims.
FDA letters assess research-use-only peptide labels alongside website claims and identify a separate sterility documentation gap.
A tularemia study identified 57 MHC-II-associated bacterial peptides in mouse cells, then tested immune responses and protection in mice.
Read peptide method validation claims in context using ICH Q2(R2), with a focus on analytical purpose, documented evidence and regulatory scope.
A focused reading of an animal peptide study shows how to keep the model, assessment time and source type visible in scientific summaries.
An in vitro GPCR study found varied β-arrestin dependence. Learn how cell models shape the interpretation of receptor internalization.
A purpose-led guide to peptide purity, identity and assay claims, grounded in ICH Q2(R2) and the scope of analytical validation.
Review model evidence for peptide deletion products and mass-overlapping variants, with clear distinctions between analytical findings and FDA draft guidance.
Read peptide COAs by matching sample identifiers, analytical purposes and supporting data, with context from peptide research and official guidance.
Examine why isolated in vitro peptide mechanisms rarely guarantee systemic results, and how to classify evidence from cell models to controlled human trials.
A 2026 in vitro study demonstrates why mass spectrometry alone cannot establish peptide purity, highlighting the need for validated chromatographic separation.
Learn how assay sensitivity, reference ligands, and cell models influence the interpretation of peptide signaling bias during in vitro laboratory experiments.
An evidence-based review explaining why peptide identity testing requires orthogonal analytical methods, featuring ICH guidelines and LC-UV separation data.
A practical framework for evaluating peptide research updates. Learn to distinguish peer-reviewed studies, preprints, and draft regulatory guidances.
Learn how to read peptide research papers by identifying exact study models, understanding laboratory limits, and separating in vitro data from broad conclusions.
Understand how researchers use ICH Q2(R2) guidelines and in vitro testing to evaluate analytical method validation, verify peptide identity, and assess limits.
An evidence-based review explaining how LC-MS assigns peptide sequences and why identical molecular masses require robust chromatographic resolution for purity.
An analysis of how receptor abundance, cell type, and accessory proteins impact peptide efficacy across in vitro and engineered laboratory models.
An in vitro study of 23 synthetic peptides demonstrates why mass spectrometry cannot guarantee purity without adequate high-performance liquid chromatography.
A scientific review of how sequence nomenclature, structural modifications, and counterions affect actual peptide compound identity and laboratory documentation.
Learn how laboratories select analytical methods for peptide characterization. We examine evidence on chromatography, mass spectrometry, and method validation.
High peptide binding affinity does not guarantee cellular activation. We analyze in vitro models to explain why physical binding differs from functional signaling.
Learn how to evaluate peptide research by tracing scientific claims to their original evidence. We examine analytical transferability limits and laboratory methodology.
A review of how peptide purity is measured in laboratories, explaining why LC-UV area normalization and ICH Q2(R2) guidelines define method-dependent limits.
An in vitro study shows why a peptide purity percentage reflects specific chromatographic conditions rather than absolute molecular identity or mass.
A practical framework for reading peptide research, separating measured endpoints from broad conclusions across cellular, animal, and human study models.
Learn why a single analytical metric cannot establish complete peptide identity or purity, and how chromatography and mass spectrometry serve distinct roles.
Learn how researchers distinguish proposed pathways from measured laboratory outcomes in peptide research, utilizing in vitro and animal study models.
Learn how to read method validation evidence in analytical research. Examine how laboratories establish accuracy, precision, and robustness for testing methods.
Explore how researchers map cellular response pathways from peptide binding events. This article details isolated islet models and protein knockdown experiments.
Learn how peptide research progresses through experimental models. We examine the critical gap between preclinical mechanisms and human clinical trials.
Analyze how in vitro models and reviews define peptide signaling mechanisms, separating verified molecular triggers from theoretical biological effects.
Viking Therapeutics initiated Part 2 of an exploratory maintenance-dosing study for VK2735. Review the specific protocol design and trial limitations.
Analyze phase 3 SYNCHRONIZE-2 clinical trial outcomes for survodutide. This update details how the investigational dual agonist affected metabolic metrics.
This BPC-157 evidence profile separates preclinical laboratory mechanisms from human data, detailing the current absence of controlled clinical efficacy trials.
Learn how to evaluate peptide research by analyzing experimental models, clinical trials, and translational barriers. Explore the limits of preclinical data.
Understand why peptide receptor affinity does not equal biological efficacy. This article separates evidence from binding assays, cell studies, and animal models.
Learn how to read a research peptide certificate of analysis critically. Trace lot numbers, HPLC purity methods, and mass spectrometry data to verify results.
Learn to interpret peptide research by separating experimental models from clinical outcomes. Apply this 9-step evaluation framework to assess study strength.
Learn why peptide identity, chromatographic purity, and quantitative content require distinct analytical evidence rather than a single percentage on a COA.
A preclinical study used phage display to identify the TGP1 peptide for targeting engineered exosomes to neural stem cells in a rat spinal cord injury model.
A PLOS Biology study reports that reconstructed ancestral lactoferrin peptides show enhanced laboratory activity against drug-resistant bacterial strains.
Try another search term or reading category.
A clearer starting point
